Multi-tiered chemical proteomic maps of tryptoline acrylamide–protein interactions in cancer cells
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Covalent chemistry is a versatile approach for expanding the ligandability of the human proteome. Activity-based protein profiling (ABPP) can infer the specific residues modified by electrophilic compounds through competition with broadly reactive probes. However, the extent to which such residue-directed platforms fully assess the protein targets of electrophilic compounds in cells remains unclear. Here we evaluate a complementary protein-directed ABPP method that identifies proteins showing stereoselective reactivity with alkynylated, chiral electrophilic compounds—termed stereoprobes. Integration of protein- and cysteine-directed data from cancer cells treated with tryptoline acrylamide stereoprobes revealed generally well-correlated ligandability maps and highlighted features, such as protein size and the proteotypicity of cysteine-containing peptides, that explain gaps in each ABPP platform. In total, we identified stereoprobe binding events for >300 structurally and functionally diverse proteins, including compounds that stereoselectively and site-specifically disrupt MAD2L1BP interactions with the spindle assembly checkpoint complex leading to delayed mitotic exit in cancer cells. The ligandability of the human proteome can be expanded using covalent chemistry. A multi-tiered chemical proteomic strategy now provides in-depth maps of tryptoline acrylamide–protein interactions in cancer cells. This platform afforded the discovery of stereoselective covalent ligands for hundreds of human proteins, including compounds that disrupt protein–protein interactions regulating the cell cycle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Varadi, M., Anyango, S., Deshpande, M., Nair, S., Natassia, C., Yordanova, G., Yuan, D., Stroe, O., Wood, G., Laydon, A., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1061 · Cited by 7,850
The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences
Perez-Riverol, Y., Bai, J., Bandla, C., García-Seisdedos, D., Hewapathirana, S., Kamatchinathan, S., Kundu, D. J., Prakash, A., Frericks-Zipper, A., Eisenacher, M., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1038 · Cited by 6,125
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 2×
“More recently, the intentional pursuit of covalent chemical probes, either by targeting specific disease-relevant nucleophilic residues (for example, G12C-KRAS) 19,20 or by globally profiling the reactivity of structurally diverse electrophilic small molecules in cells 12,21–26 has begun to showcase the broad potentia…”
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · cited 1×
“…,3 R ) stere-oisomer also stereoselectively engaged a greater number of proteins isotype-restricted nucleophilic amino acids within sets of related proteins; and (3) sustained pharmacological activity that is dependent on protein turnover rather than the pharmacokinetics of small molecules 14,15 .”
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Proteome-wide covalent ligand discovery in native biological systems
Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940 · cited 3×
“…residues (for example, G12C-KRAS) 19,20 or by globally profiling the reactivity of structurally diverse electrophilic small molecules in cells 12,21–26 has begun to showcase the broad potential of covalent chemistry to expand the small-molecule interactions (or ‘ligandability’) of the human…”
Self-citationAdvances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823 · cited 1×
“…,3 R ) stere-oisomer also stereoselectively engaged a greater number of proteins isotype-restricted nucleophilic amino acids within sets of related proteins; and (3) sustained pharmacological activity that is dependent on protein turnover rather than the pharmacokinetics of small molecules 14,15 .”
Research works printed but not linked: 61
- Chakravarty, D. & Solit, D. B. Clinical cancer genomic profiling. Nat. Rev. Genet. 22, 483–501 (2021). · DOI · Paper page
- Schreiber, S. L. A chemical biology view of bioactive small molecules and a binder-based approach to connect biology to precision medicines. Isr. J. Chem. 59, 52–59 (2019). · DOI · Paper page
- Wang, Z. Z., Shi, X. X., Huang, G. Y., Hao, G. F. & Yang, G. F. Fragment-based drug discovery supports drugging ‘undruggable’ protein-protein interactions. Trends Biochem. Sci. 48, 539–552 (2023). · DOI
- St Denis, J. D., Hall, R. J., Murray, C. W., Heightman, T. D. & Rees, D. C. Fragment-based drug discovery: opportunities for organic synthesis. RSC Med. Chem. 12, 321–329 (2020). · DOI
- Lundquist, K. P., Panchal, V., Gotfredsen, C. H., Brenk, R. & Clausen, M. H. Fragment-based drug discovery for RNA targets. ChemMedChem 16, 2588–2603 (2021). · DOI
- Erlanson, D. A., Davis, B. J. & Jahnke, W. Fragment-based drug discovery: advancing fragments in the absence of crystal structures. Cell Chem. Biol. 26, 9–15 (2019). · DOI
- Bon, M., Bilsland, A., Bower, J. & McAulay, K. Fragment-based drug discovery-the importance of high-quality molecule libraries. Mol. Oncol. 16, 3761–3777 (2022). · DOI
- Wen, X., Wu, X., Jin, R. & Lu, X. Privileged heterocycles for DNA-encoded library design and hit-to-lead optimization. Eur. J. Med. Chem. 248, 115079 (2023). · DOI
- Shi, B., Zhou, Y., Huang, Y., Zhang, J. & Li, X. Recent advances on the encoding and selection methods of DNA-encoded chemical library. Bioorg. Med. Chem. Lett. 27, 361–369 (2017). · DOI
- Peterson, A. A. & Liu, D. R. Small-molecule discovery through DNA-encoded libraries. Nat. Rev. Drug Discov. 22, 699–722 (2023). · DOI · Paper page
- Chan, W. C., Sharifzadeh, S., Buhrlage, S. J. & Marto, J. A. Chemoproteomic methods for covalent drug discovery. Chem. Soc. Rev. 50, 8361–8381 (2021). · DOI
- Cuesta, A. & Taunton, J. Lysine-targeted inhibitors and chemoproteomic probes. Annu. Rev. Biochem. 88, 365–381 (2019). · DOI · Paper page
- Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R. & Gunning, P. T. Advances in covalent kinase inhibitors. Chem. Soc. Rev. 49, 2617–2687 (2020). · DOI · Paper page
- Abbasov, M. E. et al. A proteome-wide atlas of lysine-reactive chemistry. Nat. Chem. 13, 1081–1092 (2021). · DOI · Paper page
- Wang, C., Weerapana, E., Blewett, M. M. & Cravatt, B. F. A chemoproteomic platform to quantitatively map targets of lipid-derived electrophiles. Nat. Methods 11, 79–85 (2014). · DOI · Paper page
- Chen, Y. et al. Direct mapping of ligandable tyrosines and lysines in cells with chiral sulfonyl fluoride probes. Nat. Chem. 15, 1616–1625 (2023). · DOI
- Weerapana, E. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468, 790–795 (2010). · DOI · Paper page
- Gygi, S. P. et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994–999 (1999). · DOI · Paper page
- Kuljanin, M. et al. Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries. Nat. Biotechnol. 39, 630–641 (2021). · DOI · Paper page
- Grossman, E. A. et al. Covalent ligand discovery against druggable hotspots targeted by anti-cancer natural products. Cell Chem. Biol. 24, 1368–1376.e4 (2017). · DOI · Paper page
- Lazear, M. R. et al. Proteomic discovery of chemical probes that perturb protein complexes in human cells. Mol. Cell 83, 1725–1742 (2023). · DOI
- Tao, Y. et al. Targeted protein degradation by electrophilic PROTACs that stereoselectively and site-specifically engage DCAF1. J. Am. Chem. Soc. 144, 18688–18699 (2022). · DOI · Paper page
- Feldman, H. C. et al. Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain. Proc. Natl Acad. Sci. USA 119, e2208457119 (2022). · DOI · Paper page
- Kathman, S. G. et al. Remodeling oncogenic transcriptomes by small molecules targeting NONO. Nat. Chem. Biol. 19, 825–836 (2023). · DOI
- Kavanagh, M. E. et al. Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine. Nat. Chem. Biol. 18, 1388–1398 (2022). · DOI
- Darabedian, N. et al. Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor. Nat. Chem. Biol. 19, 815–824 (2023). · DOI
- Gao, Z., Chang, C., Yang, J., Zhu, Y. & Fu, Y. AP3: an advanced proteotypic peptide predictor for targeted proteomics by incorporating peptide digestibility. Anal. Chem. 91, 8705–8711 (2019). · DOI
- Lanning, B. R. et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat. Chem. Biol. 10, 760–767 (2014). · DOI · Paper page
- Niessen, S. et al. Proteome-wide map of targets of T790M-EGFR-directed covalent inhibitors. Cell Chem. Biol. 24, 1388–1400 (2017). · DOI
- Warren, A. et al. Global computational alignment of tumor and cell line transcriptional profiles. Nat. Commun. 12, 22 (2021). · DOI · Paper page
- Rostovtsev, V. V., Green, L. G., Fokin, V. V. & Sharpless, K. B. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective ‘ligation’ of azides and terminal alkynes. Angew. Chem. Int. Ed. 41, 2596–2599 (2002). · DOI · Paper page
- Tornoe, C. W., Christensen, C. & Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 67, 3057–3064 (2002). · DOI · Paper page
- Speers, A. E., Adam, G. C. & Cravatt, B. F. Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J. Am. Chem. Soc. 125, 4686–4687 (2003). · DOI · Paper page
- Teng, M., Zhou, S., Cai, C., Lupien, M. & He, H. H. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell 12, 29–38 (2021). · DOI · Paper page
- Vinogradova, E. V. & Cravatt, B. F. Multiplexed proteomic profiling of cysteine reactivity and ligandability in human T cells. STAR Protoc. 2, 100458 (2021). · DOI
- Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–576 (2017). · DOI · Paper page
- Serrano, G., Guruceaga, E. & Segura, V. DeepMSPeptide: peptide detectability prediction using deep learning. Bioinformatics 36, 1279–1280 (2020). · DOI
- Li, H. et al. Assigning functionality to cysteines by base editing of cancer dependency genes. Nat. Chem. Biol. 19, 1320–1330 (2023). · DOI · Paper page
- Taylor, C. A. T. et al. Domain-swapping switch point in Ste20 protein kinase SPAK. Biochemistry 54, 5063–5071 (2015). · DOI
- Tan, L., Yu, J. T. & Tan, L. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J. Neurol. Sci. 323, 1–8 (2012). · DOI · Paper page
- Dewulf, J. P. et al. Urine metabolomics links dysregulation of the tryptophan-kynurenine pathway to inflammation and severity of COVID-19. Sci. Rep. 12, 9959 (2022). · DOI
- Thomas, T. et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight 5, e140327 (2020). · DOI · Paper page
- Hu, L. J. et al. A simple HPLC-MS/MS method for determination of tryptophan, kynurenine and kynurenic acid in human serum and its potential for monitoring antidepressant therapy. J. Anal. Toxicol. 41, 37–44 (2017). · DOI
- Dobrovolsky, V. N. et al. Effect of arylformamidase (kynurenine formamidase) gene inactivation in mice on enzymatic activity, kynurenine pathway metabolites and phenotype. Biochim. Biophys. Acta 1724, 163–172 (2005). · DOI
- Bachovchin, D. A. et al. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. Proc. Natl Acad. Sci. USA 107, 20941–20946 (2010). · DOI · Paper page
- Westhorpe, F. G., Tighe, A., Lara-Gonzalez, P. & Taylor, S. S. p31comet-mediated extraction of Mad2 from the MCC promotes efficient mitotic exit. J. Cell Sci. 124, 3905–3916 (2011). · DOI
- Hagan, R. S. et al. p31comet acts to ensure timely spindle checkpoint silencing subsequent to kinetochore attachment. Mol. Biol. Cell 22, 4236–4246 (2011). · DOI
- Lok, T. M. et al. Mitotic slippage is determined by p31comet and the weakening of the spindle-assembly checkpoint. Oncogene 39, 2819–2834 (2020). · DOI
- Yang, M. et al. p31comet blocks Mad2 activation through structural mimicry. Cell 131, 744–755 (2007). · DOI · Paper page
- Abdel-Salam, G. M. H. et al. Biallelic MAD2L1BP (p31comet) mutation is associated with mosaic aneuploidy and juvenile granulosa cell tumors. JCI Insight 8, e170079 (2023). · DOI
- Browne, C. M. et al. A chemoproteomic strategy for direct and proteome-wide covalent inhibitor target-site identification. J. Am. Chem. Soc. 141, 191–203 (2019). · DOI · Paper page
- Wozniak, J. M. et al. Enhanced mapping of small-molecule binding sites in cells. Nat. Chem. Biol. 20, 823–834 (2024). · DOI
- Mons, E., Kim, R. Q. & Mulder, M. P. C. Technologies for direct detection of covalent protein–drug adducts. Pharmaceuticals 16, 547 (2023). · DOI
- Giansanti, P., Tsiatsiani, L., Low, T. Y. & Heck, A. J. Six alternative proteases for mass spectrometry-based proteomics beyond trypsin. Nat. Protoc. 11, 993–1006 (2016). · DOI · Paper page
- Abegg, D. et al. Chemoproteomic profiling by cysteine fluoroalkylation reveals myrocin G as an inhibitor of the nonhomologous end joining DNA repair pathway. J. Am. Chem. Soc. 143, 20332–20342 (2021). · DOI
- Tessier, R. et al. Ethynylation of cysteine residues: from peptides to proteins in vitro and in living cells. Angew. Chem. Int. Ed. 59, 10961–10970 (2020). · DOI · Paper page
- Motiwala, H. F., Kuo, Y. H., Stinger, B. L., Palfey, B. A. & Martin, B. R. Tunable heteroaromatic sulfones enhance in-cell cysteine profiling. J. Am. Chem. Soc. 142, 1801–1810 (2020). · DOI · Paper page
- Cuesta, A., Wan, X., Burlingame, A. L. & Taunton, J. Ligand conformational bias drives enantioselective modification of a surface-exposed lysine on Hsp90. J. Am. Chem. Soc. 142, 3392–3400 (2020). · DOI · Paper page
- Jacobs, A. T. & Marnett, L. J. Systems analysis of protein modification and cellular responses induced by electrophile stress. Acc. Chem. Res. 43, 673–683 (2010). · DOI · Paper page
- Békés, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022). · DOI · Paper page
- Zhang, Y. et al. Expanding the ligandable proteome by paralog hopping with covalent probes. Preprint at bioRxiv https://doi.org/10.1101/2024.01.18.576274 (2024). · DOI
Cited by
Ogasawara, D., Konrad, D. B., Tan, Z. Y., Carey, K. L., Luo, J., Won, S. J., Li, H., Carter, T. R., DeMeester, K. E., Njomen, E., et al. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.10.005 · Cited by 31
Self-citationStructural and mechanistic analysis of covalent ligands targeting the RNA-binding protein NONO
Lindsey, G. L., Hockley, T. K., Gomez, A. V., Marshall, A. C., Brothers, W. R., Finney, C. T., Gross, J., Fox, A. H., Yeo, G. W., Melillo, B., et al. (2026) · Cell Chemical Biology · doi:10.1016/j.chembiol.2025.12.010 · Cited by 6
Self-citation
Metadata
- Authors
- Njomen, E., Hayward, R. E., DeMeester, K. E., Ogasawara, D., Dix, M. M., Nguyen, T., Ashby, P., Simon, G. M., Schreiber, S. L., Melillo, B., & Cravatt, B. F.
- Venue
- Nature Chemistry
- Published
- 2024-08-13
- Volume
- 16
- Issue
- 10
- Pages
- 1592-1604
- ISSN
- 1755-4330 (ISSN-L)
- 1755-4349
- OpenAlex
- W4401548057
- Cited by
- 53
- References
- 21
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19 AI142784)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA231991, OT2 CA278692)
- Cancer Research UK (CGCATF-2021/100021)
- Howard Hughes Medical Institute (GT15176)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi-tiered chemical proteomic maps of tryptoline acrylamide–protein interactions in cancer cells. https://app.cochat.ai/papers/10.1038/s41557-024-01601-1
- The paper
- Njomen, E., Hayward, R. E., DeMeester, K. E., Ogasawara, D., Dix, M. M., Nguyen, T., Ashby, P., Simon, G. M., Schreiber, S. L., Melillo, B., & Cravatt, B. F. (2024). Multi-tiered chemical proteomic maps of tryptoline acrylamide–protein interactions in cancer cells. Nature Chemistry. https://doi.org/10.1038/s41557-024-01601-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.